NYTIMES (Christina Jewett) - Divisive F.D.A. Vaccine Regulator Is Resigning
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.
NPR (The Associated Press) - Trump administration's embattled FDA vaccine chief is leaving for the second time
The FDA's controversial vaccine chief, Dr. Vinay Prasad, is leaving the agency. It's the second time he has abruptly departed following decisions involving the review of vaccinations and specialty drugs.
ABCNEWS - FDA vaccine chief Dr. Vinay Prasad to leave agency next month
It's the second time Prasad's departure has been announced.
WASHINGTONPOST (Rachel Roubein) - Controversial top vaccine regulator to depart FDA
Vinay Prasad, the top regulator overseeing vaccines and complex treatments for difficult diseases, had previously lost his job in July before getting it back less than two weeks later.
THENATIONALPULSE (Pulse Wires) - FDA Reverses Rejection of Moderna MRNA Flu Vax, Will Now Review for Approval.
PULSE POINTSWHAT HAPPENED: The U.S. Food and Drug Administration (FDA) has reversed a prior decision from last week and will review Moderna’s flu vaccine for possible approval.WHO WAS INVOLVED: Moderna, the FDA, Dr. Vinay Prasad, and FDA Commissioner Dr. Marty Makary.WHEN & WHERE: February 18, 2026, United States.IMPACT: The potential approval could make the vaccine […] The post FDA Reverses Rejection of Moderna MRNA Flu Vax, Will Now Review for Approval. appeared first on The National Pulse .
PULSE POINTS WHAT HAPPENED: The U.S. Food and Drug Administration (FDA) has reversed a prior decision from last week and will review Moderna’s flu vaccine for possible approval. WHO WAS INVOLVED: Moderna, the FDA, Dr. Vinay Prasad, and FDA Commissioner Dr. Marty Makary. WHEN & WHERE: February 18, 2026, United States. IMPACT: The potential approval could make the vaccine available for older adults in the upcoming flu season. IN FULL Moderna has announced that the U.S. Food and Drug Administration (FDA ) has decided to review its flu vaccine, reversing its previous rejection from last week. The initial rejection cited flaws in Moderna’s research design, but subsequent discussions led the FDA to agree to reconsider. Regulators are now…Open